Astellas Turns Up Heat On Bid To Acquire CV Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
If Japanese pharma’s gambit fails, it could be in breach of contract with CVT and lose rights to Lexiscan.
You may also be interested in...
Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
Astellas Pharma is going hostile again. The Japanese drug maker launched a $3.5 billion unsolicited bid for OSI Pharmaceuticals on March 1 to gain a foothold in the oncology market
Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
Japan's second-biggest pharma offers $3.5 billion to OSI shareholders after 13 months of rejection by the target's management.
Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
Japan's second-biggest pharma offers $3.5 billion to OSI shareholders after 13 months of rejection by the target's management.